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Background: Tamoxifen has a remarkable impact on the outcome of oestrogen receptor (ER)-positive breast
cancer. Without proven benefits, tamoxifen is occasionally prescribed for women with ER-negative disease. This
population-based study aims to estimate the impact of tamoxifen on the outcome of ER-negative disease.
Methods: We identified all women (n = 528) diagnosed with ER-negative invasive breast cancer between 1995 and
2005. With Cox regression analysis, we calculated breast cancer mortality risks of patients treated with tamoxifen
compared with those treated without tamoxifen. We adjusted these risks for the individual probabilities (propensity
scores) of having received tamoxifen.
Results: Sixty-nine patients (13%) with ER-negative disease were treated with tamoxifen. Five-year disease-specific
survival for women treated with versus without tamoxifen were 62% [95% confidence interval (CI) 48% to 76%] and
79% (95% CI 75% to 83%), respectively (PLog-rank < 0.001). For ER-negative patients, risk of death from breast cancer
was significantly increased in those treated with tamoxifen compared with patients treated without tamoxifen (adjusted
hazard ratio = 1.7, 95% CI 1.1–2.9, P = 0.031).
Conclusion: Our results show that patients with ER-negative breast cancer treated with tamoxifen have an increased
risk of death from their disease. Tamoxifen use should be avoided for these patients.
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introduction
The introduction of adjuvant hormonal therapy, in particular
tamoxifen, has been one of the major breakthroughs in the
fight against breast cancer mortality. For women with
oestrogen receptor (ER)-positive breast cancer, 5 years of
tamoxifen in an adjuvant setting decreases the risk of death
from the disease by 31% [1]. In addition, tamoxifen
reduces the risk of contralateral breast cancer by almost
50% [2].
According to the results of the first meta-analysis of the Early
Breast Cancer Trialists’ Collaborative Group, use of tamoxifen
seemed to have a small beneficial effect in patients with
ER-negative tumours (i.e. tumours with low or no expression
of ER) [2]. A more recent overview of randomised trials
showed a nonsignificantly 4% increased risk of death from
breast cancer in ER-negative patients treated with tamoxifen
during 5 years [1].
Still, over the last years, it is estimated that >10% of patients
with ER-negative disease were treated with tamoxifen, either to
reduce the risk of contralateral disease or because of a small
proportion (1–9%) of tumour cells expressing ER [3].
In this study, we aimed to evaluate the effect of tamoxifen on
the outcome of ER-negative breast cancer outside the context of
clinical trials.
methods
We used data from the Geneva Cancer Registry, which records all incident
cancer cases occurring in the population of the canton (447 000
inhabitants in 2007). The registry collects information from various sources
and the percentage of patients recorded from death certificates only is
low (<2%). All hospitals, pathology laboratories, and practitioners are
requested to report every cancer case. Trained registrars systematically
abstract data from medical and laboratory records. Physicians regularly
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Recorded data include sociodemographic information, method of
detection, tumour characteristics, stage of disease at diagnosis, treatment,
survival status, and cause of death.
The registry regularly assesses survival. The index date refers to the date
of confirmation of diagnosis or the date of hospitalisation if it preceded the
diagnosis and was related to the disease. Active follow-up is carried out
yearly using the files of the Cantonal Population Office, which is in charge
of the registration of the resident population. Cause of death is established
from clinical records and coded according to the World Health
Organisation classification [4]. Follow-up was completed on 31 December
2006.
We identified all patients diagnosed with invasive ER-negative breast
cancer from 1 January 1995 to 31 December 2005. We defined tumours as
ER negative when <10% of the tumour cells expressed ER by
immunohistochemical assay.
Variables of interest were age, social class (high, middle, low, unknown),
sector of care (private, public), and period of diagnosis. For staging, we
used the pathological tumour–node–metastasis classification system or,
when not available, the clinical tumour–node–metastasis classification [5].
Tumour differentiation (grade) was classified as good (grade 1), moderate
(grade 2), poor (grade 3), or unknown. Progesterone receptor (PgR) status
was considered negative when <10% of the tumour cells expressed PgR.
Locoregional therapy was categorised as breast-conserving surgery
followed by radiotherapy, mastectomy with or without radiotherapy, and
other (i.e. tumourectomy without radiotherapy). Use of chemotherapy was
categorised as yes versus no. Except for the last year of the study period
when antiaromatase was introduced in routine care practice, hormonal
therapy consisted in tamoxifen only and was classified as tamoxifen yes
versus no.
We compared patients treated with tamoxifen with those treated without
tamoxifen. For both groups, we calculated disease-specific survival rates
using Kaplan–Meier analysis and tested survival differences with log-rank
test. With chi-square test, we identified all sociodemographic, tumour,
and treatment characteristics that were significantly different between the
two groups. We calculated the probability of having received tamoxifen for
each patient, including in the logistic regression model all variables
univariately associated with the administration of tamoxifen (propensity
score) [6]. With Cox regression analysis, we calculated the risk [hazard
ratio (HR)] of death from breast cancer for patients treated with versus
without tamoxifen. We adjusted these risks for the predicted probabilities
of tamoxifen.
results
Of the 528 ER-negative breast cancer patients included in this
study, 69 women (13%) were treated with tamoxifen. ER-
negative patients aged ‡70 years were more likely to receive
tamoxifen, as were patients detected fortuitously or following
symptoms, patients with advanced stage at diagnosis, unknown
tumour differentiation, or tumours expressing PgR. Patients
treated with tamoxifen were less likely to receive locoregional
treatment according to the standard guidelines (i.e.
mastectomy or breast-conserving surgery followed by breast
irradiation) and chemotherapy (Table 1). All these factors were
included in the logistic model to calculate the individual
probabilities of having received tamoxifen.
The median follow-up was 47 months. Five- and 10-year
disease-specific survival rates were 62% (95% confidence
interval (CI) 48% to 76%) and 47% (95% CI 27% to 67%),
respectively, for women treated with tamoxifen, and 79% (95%
CI 75% to 83%) and 74% (95% CI 68% to 80%), respectively,
for women treated without tamoxifen (Figure 1). These
differences were highly, statistically significant with P-value log-
rank tests <0.001.
In the unadjusted analysis, patients who received tamoxifen
had a more than two-fold increased risk of death from breast
cancer compared with those who did not (HR 2.2, 95% CI
1.4–3.4). This result remained similar after adjustment for
propensity scores to have received tamoxifen. Additional
adjustment for all other prognostic factors did not modify the
HR value, but results were no longer significant. HRs did not
change after excluding women with distant metastases and
women who did not undergo surgery for their breast cancer
(Table 2). The increased mortality risk linked to use of
tamoxifen was limited to patients with PgR-negative tumours
(n = 478, HR 2.6, 95% CI 1.6–4.3) while in the subgroup of
women with PgR-positive tumours (n = 50), use of tamoxifen
was not significantly associated with an increased breast
cancer-specific mortality risk (HR 1.4, 95% CI 0.4–4.7). The
Table 1. Patient and tumour characteristics by use of tamoxifen for 528




n = 69 (%)
No,
n = 459 (%)
Age (years) P = 0.0110
<50 20 (10) 159 (89)
50–69 25 (11) 213 (90)
70+ 24 (22) 87 (78)
Method of detection P = 0.0274
Breast self-examination 27 (10) 253 (90)
Clinical examination or
screening
20 (15) 114 (85)
Symptoms/fortuitous 22 (19) 92 (81)
Stage P = 0.0114
I 12 (8) 136 (92)
II 27 (12) 202 (88)
III 13 (15) 71 (85)
IV 10 (24) 31 (76)
Unknown 7 (27) 19 (73)
Differentiation P = 0.0002
Good 7 (23) 24 (77)
Moderate 24 (16) 129 (84)
Poor 24 (8) 270 (92)
Unknown 14 (28) 36 (72)
Progesterone receptor status P < 0.0001
Positive 20 (40) 30 (60)
Negative 49 (10) 429 (90)
Locoregional therapy P = 0.0012
Standarda 51 (11) 405 (89)
Other 18 (25) 54 (75)
Chemotherapy P = 0.0025
No 30 (20) 119 (80)
Yes 39 (10) 340 (90)
aStandard locoregional therapy: breast-conserving surgery associated with
radiotherapy and mastectomy with or without radiotherapy.
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number of patients with low expression of ER (1%–9% of
tumour cells expressing ER) was low (n = 29); therefore, we
could not carry out a meaningful subgroup analysis.
discussion
The results of this study show that the use of tamoxifen in
women with ER-negative breast cancer is associated with an
increased risk of death from the disease. The deleterious effect
of tamoxifen was limited to patients with ER- and PgR-negative
tumours.
Our results are in contrast with those reported in the first
meta-analysis by the Early Breast Cancer Trialists’ Collaborative
Group [2]. The results of this study showed that use of adjuvant
tamoxifen seemed to have a small benefit in patients with
ER-negative tumours (low or no ER). Use of tamoxifen reduced
the risk of recurrent disease by 9% (P = 0.03) and the mortality
risk by 6% (not statistically significant). However, the
investigators were uncertain whether this represented a real
benefit of tamoxifen in truly ER-negative women or only in
women whose tumours would have had a low, but detectable
level of ER by current methods.
Several years later, the same Early Breast Cancer Trialists’
Collaborative Group published an updated overview of
randomised trials on the effects of chemotherapy and hormonal
therapy on long-term recurrence and survival after early breast
cancer [1]. They analysed 12 trials including 15 017 women
and compared the effect of 5 years of adjuvant tamoxifen use
versus no hormonal treatment. This time the authors found that
1- to 2-year use of tamoxifen in ER-poor disease was associated
with a nonsignificant 9% reduced risk of death from breast
cancer, while 5-year use of adjuvant tamoxifen was associated
with a nonsignificantly 4% increased risk of death from breast
cancer. The authors stratified by PgR status (PgR-positive versus
PgR-poor breast cancer) and observed that tamoxifen was
associated with a 13% nonsignificantly increased risk of local
recurrence and mortality in ER/PgR-negative disease.
This meta-analysis included one trial which specifically
investigated the effect of tamoxifen in patients with ER-negative
breast cancer [7]. In premenopausal women, survival of
patients treated with chemotherapy and tamoxifen was
significantly lower than that of patients treated with
chemotherapy alone.
More recently, Hutchins et al. [8] investigated the impact of
adjuvant chemotherapy with and without tamoxifen in node-
negative high-risk breast cancer and found that the effect of
tamoxifen was modified by the hormone receptor status.
For hormone (ER and PgR) receptor-positive breast cancer
patients, tamoxifen was beneficial, but for ER- and
PgR-negative breast cancer patients, tamoxifen was deleterious
(HR for disease-free survival 0.81, 95% CI 0.64–1.03).
In the German Adjuvant Breast Cancer Group trial IV D-93,
postmenopausal patients with ER- and PgR-negative disease
were randomly assigned to 5 years of tamoxifen versus no
tamoxifen following chemotherapy. The risk of recurrence
among patients in the tamoxifen group was increased by 13%
(HR 1.13, 95% CI 0.87–1.48, P = 0.34) [9].
In a study from the International Breast Cancer Study Group
Trial, premenopausal women with node-positive disease who
Figure 1. Disease-specific survival1 according to treatment with or
without tamoxifen among 528 women with oestrogen receptor-negative
breast cancer.
Table 2. Risk (HR)a of death from oestrogen receptor-negative breast
cancer for women treated with tamoxifen compared with those treated
without tamoxifen (Geneva Cancer Registry, 1995–2005)




All breast cancers (n = 528)
No 459 88 1 1
Yes 69 24 2.2 (1.4–3.4) 1.7 (1.1–2.9)
P = 0.0007 P = 0.0305
Stages I–III breast cancer only (n = 461)
No 409 63 1 1
Yes 52 13 1.9 (1.1–3.5) 2.0 (1.0–3.7)
P = 0.0306 P = 0.0362
Operated breast cancer only (n = 484)
No 430 72 1 1
Yes 54 15 1.9 (1.1–3.3) 1.8 (1.0–3.2)
P = 0.0227 P = 0.0629
PgR-positive breast cancer only (n = 50)
No 30 6 1 1
Yes 20 5 1.4 (0.4–4.7) 1.1 (0.3–3.8)
P = 0.5616 P = 0.8995
PgR-negative breast cancer only (n = 478)
No 429 19 1 1
Yes 49 82 2.6 (1.6–4.3) 1.8 (1.0–3.1)
P = 0.0001 P = 0.0482
aHRs were derived from Cox model adjusted for the individual probabilities
(propensity scores) to have received tamoxifen; only death from breast
cancer was considered.
HR, hazard ratio; PS, propensity scores; PgR, progesterone receptor.
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received chemotherapy were randomly assigned to receive
further adjuvant tamoxifen during 5 years versus no additional
treatment. Tamoxifen had a detrimental effect on disease-free
survival in patients with ER-negative tumours compared with
no tamoxifen (HR 2.10, 95% CI 1.03–4.29, P = 0.04) [10].
A pooled analysis of two British randomised trials, which
included ER-negative node-positive and node-negative
postmenopausal patients and ER-negative node-negative
premenopausal patients, showed that 2 years of tamoxifen
(versus no adjuvant treatment) was beneficial only in patients
whose tumours expressed PgR [11].
In our study, tamoxifen did not have a detrimental effect in
the small group of patients with PgR-positive disease, which is
in accordance with previous studies [1, 11].
In addition to the growing evidence that the effect of
tamoxifen could be deleterious on the prognosis of ER-negative
tumours, there are also data suggesting that it could influence
carcinogenesis of ER-negative tumours. In particular, Esserman
et al. [12] hypothesised that the preventive use of tamoxifen in
high-risk women decreases the risk of ER-positive breast
cancer, but may actually increase the risk of ER-negative breast
cancer.
To our knowledge, this is the first study assessing the effect of
tamoxifen on patients with ER-negative breast cancer in
a population-based setting. Clinical trials usually involve highly
specialised physicians and patients are treated according to the
standard protocols under relatively optimal conditions.
Therefore, it is important to confirm results of clinical trials in
daily care practice. However, since our study is not
a randomised trial, patients receiving tamoxifen were by no
means comparable with those not receiving tamoxifen. With
propensity score analysis, we calculated for each patient the
individual probability of having received tamoxifen, based on
demographic, tumour, and treatment characteristics. In
multivariate analysis, we adjusted for propensity scores, thus
rendering comparable patients treated with versus without
tamoxifen. Nevertheless, there maybe other factors associated
with the prescription of tamoxifen for which we did not
account. However, even though some residual confounding
maybe present, it is unlikely that this could explain the doubled
risk of death from breast cancer in ER-negative patients
treated with tamoxifen. Also, other prognostic factors, like
overexpression of HER-2 and presence of vascular/lymphatic
invasion, were not available for the study period. Another
limitation of our study was the lack of pathological review and
updated centralised assessment of steroid receptors. In
particular, the possibility of misclassification of ER-positive
tumours into the ER-negative tumours exists [13].
Furthermore, the immunohistochemical assay used in our
patients routinely assesses ER-a but not ER-b, the latter being
positive in a nonnegligible proportion of ER-a-negative
tumours. ER-b expression has been recently associated with
tamoxifen response in ER-a-negative breast cancer [14].
Both these biases would rather dilute the increased mortality
risk observed in ER-a-negative breast cancer. Finally,
a recent study on quality of ER assessment concluded that ER
assay results from pathological reports are reasonable
alternative to central laboratory ER testing for population-
based studies [15].
The effects of oestrogen and hormonal manipulation on
cancer prevention, promotion, and growth are far from being
completely understood. More than 20 years ago, Fisher et al. [7]
postulated that if oestrogen acted only through ER, and if the
effect of tamoxifen was only to block this pathway, there would
hardly be any reason to believe that tamoxifen could have an
adverse effect, particularly in women with ER-negative disease.
Today, we know that tamoxifen also acts on growth factor
signaling pathways, including tumour growth factor a and b,
insulin-like growth factor-II, and epidermal growth factor
receptors (EGFRs) [16, 17]. Also, the dual mechanism of
tamoxifen is well established, as it acts both as ER antagonist
and ER agonist [18]. Tamoxifen has partial agonist/antagonist
activity through ER-a, but a pure antagonist effect through
ER-b [19]. It has been recently shown in vitro that the agonist
activity of tamoxifen on cell proliferation was strongly
increased in cells expressing high level of both HER-2 (member
of the EGFR family) and ER coactivator called amplified in
breast cancer-1 (AIB1). This agonist activity of tamoxifen
results in important tumour growth stimulation [20]. Both
HER-2 receptor and AIB1 coactivator are more frequently
expressed in ER-negative disease and associated with tamoxifen
resistance [11, 21, 22]. Of note, ER-positive breast tumours
with amplification of HER-2 apparently may not respond
favourably to tamoxifen in an adjuvant setting [23–26].
To date, aromatase inhibitors are superior to tamoxifen as
adjuvant treatment of postmenopausal ER-positive breast
cancer and their efficacy in a preventing setting is under study
[27–30]. Since aromatase inhibitors are increasingly being
favoured to tamoxifen, one could expect the number of ER-
negative breast cancer patients treated with aromatase
inhibitors to increase. However, the impact of aromatase
inhibitors on the outcome of ER-negative disease is still
unknown. This study on tamoxifen can make clinicians aware
of the putative risk of overindication of antioestrogen or
antiaromatase treatment. Also, a better understanding of the
biological mechanism behind the detrimental effect of
tamoxifen on ER- and PgR-negative breast cancer could help to
better determine factors linked to growth of breast tumour
cells.
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